Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
The city of Meriden, Connecticut, filed a lawsuit in federal court on Monday, accusing 20 companies, including major drug manufacturers such as CVS Health Corp., Eli Lilly and Co., and Novo Nordisk ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...
Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...
Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and ...
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...
Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...